Earli is dedicated to transforming cancer management by leveraging advanced genetic technology to identify and combat cancer cells more effectively. The company develops innovative genetic constructs based on research from Stanford's Gambhir lab, which enable early detection and treatment of cancer by inducing cancer cells to reveal themselves and activate therapeutic responses. Earli's platform utilizes synthetic promoter-reporter systems that selectively trigger in dysregulated cells, prompting them to produce markers for imaging or proteins that stimulate the immune response. Through this approach, Earli aims to shift cancer diagnosis and treatment from prolonged observation to immediate intervention, significantly improving patient outcomes. The organization operates at the intersection of biotechnology and patient care, backed by substantial funding from leading investors and guided by a team of renowned experts in oncology and immunology.